Patient Information

Elderly individuals who consumed a vegan diet were at an adjusted 72% lower risk of prevalent left ventricular diastolic dysfunction (as well as 70% lower risk of left ventricular hypertrophy) than were nonvegetarians in the Adventist Health Study-2. Find out what else this ongoing observational epidemiologic study revealed at Cardiology News: http://www.ecardiologynews.com/specialty-focus/heart-failure/single-article-page/vegetarianism-may-protect-against-heart-failure/8d9a2e9a1b5d58c16fdab189b70d3295.html.

Elderly individuals who consumed a vegan diet were at an adjusted 72% lower risk of prevalent left ventricular diastolic dysfunction (as well as 70% lower risk of left ventricular hypertrophy) than were nonvegetarians in the Adventist Health Study-2. Find out what else this ongoing observational epidemiologic study revealed at Cardiology News: http://www.ecardiologynews.com/specialty-focus/heart-failure/single-article-page/vegetarianism-may-protect-against-heart-failure/8d9a2e9a1b5d58c16fdab189b70d3295.html.

Elderly individuals who consumed a vegan diet were at an adjusted 72% lower risk of prevalent left ventricular diastolic dysfunction (as well as 70% lower risk of left ventricular hypertrophy) than were nonvegetarians in the Adventist Health Study-2. Find out what else this ongoing observational epidemiologic study revealed at Cardiology News: http://www.ecardiologynews.com/specialty-focus/heart-failure/single-article-page/vegetarianism-may-protect-against-heart-failure/8d9a2e9a1b5d58c16fdab189b70d3295.html.

Insulin pumps are a major advance in diabetes management, making insulin dosing easier and more accurate, and providing great flexibility, safety, and efficacy for people who need basal-bolus insulin therapy. This article reviews who benefits from a pump and how best to manage patients who have one.  Read the full article at the Cleveland Clinic Journal of Medicine: http://www.ccjm.org/topics/diabetes-endocrinology-metabolism/single-article-page/insulin-pumps-beyond-basal-bolus/dca4da0316f284a0e3b7762b4f2f37ef.html.

Insulin pumps are a major advance in diabetes management, making insulin dosing easier and more accurate, and providing great flexibility, safety, and efficacy for people who need basal-bolus insulin therapy. This article reviews who benefits from a pump and how best to manage patients who have one.  Read the full article at the Cleveland Clinic Journal of Medicine: http://www.ccjm.org/topics/diabetes-endocrinology-metabolism/single-article-page/insulin-pumps-beyond-basal-bolus/dca4da0316f284a0e3b7762b4f2f37ef.html.

Insulin pumps are a major advance in diabetes management, making insulin dosing easier and more accurate, and providing great flexibility, safety, and efficacy for people who need basal-bolus insulin therapy. This article reviews who benefits from a pump and how best to manage patients who have one.  Read the full article at the Cleveland Clinic Journal of Medicine: http://www.ccjm.org/topics/diabetes-endocrinology-metabolism/single-article-page/insulin-pumps-beyond-basal-bolus/dca4da0316f284a0e3b7762b4f2f37ef.html.

This patient handout from the Agency for Healthcare Research and Quality discusses 4 non-pharmacologic treatment options for patients who haven’t responded to 2 or more antidepressants. The handout describes the benefits and side effects of electroconvulsive therapy, vagus nerve stimulation, repetitive transcranial magnetic stimulation, and “talk” therapy. There’s also a section on things to think about when working with a physician to select the best option. http://effectivehealthcare.ahrq.gov/ehc/products/76/1011/ref_dep_cons_fin_to_post.pdf.

This patient handout from the Agency for Healthcare Research and Quality discusses 4 non-pharmacologic treatment options for patients who haven’t responded to 2 or more antidepressants. The handout describes the benefits and side effects of electroconvulsive therapy, vagus nerve stimulation, repetitive transcranial magnetic stimulation, and “talk” therapy. There’s also a section on things to think about when working with a physician to select the best option. http://effectivehealthcare.ahrq.gov/ehc/products/76/1011/ref_dep_cons_fin_to_post.pdf.

This patient handout from the Agency for Healthcare Research and Quality discusses 4 non-pharmacologic treatment options for patients who haven’t responded to 2 or more antidepressants. The handout describes the benefits and side effects of electroconvulsive therapy, vagus nerve stimulation, repetitive transcranial magnetic stimulation, and “talk” therapy. There’s also a section on things to think about when working with a physician to select the best option. http://effectivehealthcare.ahrq.gov/ehc/products/76/1011/ref_dep_cons_fin_to_post.pdf.

It’s easy for patients to become confused by the different medications that are available to manage their chronic obstructive pulmonary disease (COPD). This handout from the American Lung Association (http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/copd/diagnosing-and-treating/managing-your-copd-medications.html) identifies the different COPD medications (eg, bronchodilators, anti-inflammatories, combination drugs) and how each works.

It’s easy for patients to become confused by the different medications that are available to manage their chronic obstructive pulmonary disease (COPD). This handout from the American Lung Association (http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/copd/diagnosing-and-treating/managing-your-copd-medications.html) identifies the different COPD medications (eg, bronchodilators, anti-inflammatories, combination drugs) and how each works.

It’s easy for patients to become confused by the different medications that are available to manage their chronic obstructive pulmonary disease (COPD). This handout from the American Lung Association (http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/copd/diagnosing-and-treating/managing-your-copd-medications.html) identifies the different COPD medications (eg, bronchodilators, anti-inflammatories, combination drugs) and how each works.

Dabigatran (a direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (direct activated factor X inhibitors) are increasingly being used in clinical practice. Compared with vitamin K antagonists, they are more convenient, do not require laboratory monitoring, have limited drug and food interactions, and have fixed dosages suitable for most patients. This review from the Cleveland Clinic Journal of Medicine summarizes the clinically relevant characteristics of these new oral anticoagulants and provides guidance on their usage: http://www.ccjm.org/current-issue/issue-single-view/the-new-oral-anticoagulants-reasonable-alternatives-to-warfarin/26c19370e96b6f1a068a6c1a2974e737.html.

Dabigatran (a direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (direct activated factor X inhibitors) are increasingly being used in clinical practice. Compared with vitamin K antagonists, they are more convenient, do not require laboratory monitoring, have limited drug and food interactions, and have fixed dosages suitable for most patients. This review from the Cleveland Clinic Journal of Medicine summarizes the clinically relevant characteristics of these new oral anticoagulants and provides guidance on their usage: http://www.ccjm.org/current-issue/issue-single-view/the-new-oral-anticoagulants-reasonable-alternatives-to-warfarin/26c19370e96b6f1a068a6c1a2974e737.html.

Dabigatran (a direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (direct activated factor X inhibitors) are increasingly being used in clinical practice. Compared with vitamin K antagonists, they are more convenient, do not require laboratory monitoring, have limited drug and food interactions, and have fixed dosages suitable for most patients. This review from the Cleveland Clinic Journal of Medicine summarizes the clinically relevant characteristics of these new oral anticoagulants and provides guidance on their usage: http://www.ccjm.org/current-issue/issue-single-view/the-new-oral-anticoagulants-reasonable-alternatives-to-warfarin/26c19370e96b6f1a068a6c1a2974e737.html.

A brochure from the Obesity Action Coalition can help reinforce your discussions with patients about their increased risk of type 2 diabetes and other conditions when they suffer from obesity. This brochure lists symptoms that suggest a patient has or is developing type 2 diabetes, and provides a fasting blood sugar chart. The brochure is available at: http://www.obesityaction.org/educational-resources/brochures-and-guides/understanding-excess-weight-and-its-role-in-type-2-diabetes-brohure.

A brochure from the Obesity Action Coalition can help reinforce your discussions with patients about their increased risk of type 2 diabetes and other conditions when they suffer from obesity. This brochure lists symptoms that suggest a patient has or is developing type 2 diabetes, and provides a fasting blood sugar chart. The brochure is available at: http://www.obesityaction.org/educational-resources/brochures-and-guides/understanding-excess-weight-and-its-role-in-type-2-diabetes-brohure.

A brochure from the Obesity Action Coalition can help reinforce your discussions with patients about their increased risk of type 2 diabetes and other conditions when they suffer from obesity. This brochure lists symptoms that suggest a patient has or is developing type 2 diabetes, and provides a fasting blood sugar chart. The brochure is available at: http://www.obesityaction.org/educational-resources/brochures-and-guides/understanding-excess-weight-and-its-role-in-type-2-diabetes-brohure.

Three simple, routinely collected measurements together provide insight into the risk faced by community-dwelling patients hospitalized for acute decompensated heart failure, according to data collected from 3620 patients at one US center. The 3 measures are blood urea nitrogen, systolic blood pressure, and serum creatinine.

Using dichotomous cutoffs first calculated a decade ago, these 3 parameters distinguish up to an eight-fold range of postdischarge mortality during the 30 or 90 days following an index hospitalization, and up to a four-fold range of risk for rehospitalization for heart failure during the ensuing 30 or 90 days. More on this study is available at Cardiology News: http://www.ecardiologynews.com/specialty-focus/heart-failure/single-article-page/aha-three-measures-risk-stratify-acute-heart-failure/db179da4df9d20baa44be88152c1598f.html.

Three simple, routinely collected measurements together provide insight into the risk faced by community-dwelling patients hospitalized for acute decompensated heart failure, according to data collected from 3620 patients at one US center. The 3 measures are blood urea nitrogen, systolic blood pressure, and serum creatinine.

Using dichotomous cutoffs first calculated a decade ago, these 3 parameters distinguish up to an eight-fold range of postdischarge mortality during the 30 or 90 days following an index hospitalization, and up to a four-fold range of risk for rehospitalization for heart failure during the ensuing 30 or 90 days. More on this study is available at Cardiology News: http://www.ecardiologynews.com/specialty-focus/heart-failure/single-article-page/aha-three-measures-risk-stratify-acute-heart-failure/db179da4df9d20baa44be88152c1598f.html.

Three simple, routinely collected measurements together provide insight into the risk faced by community-dwelling patients hospitalized for acute decompensated heart failure, according to data collected from 3620 patients at one US center. The 3 measures are blood urea nitrogen, systolic blood pressure, and serum creatinine.

Using dichotomous cutoffs first calculated a decade ago, these 3 parameters distinguish up to an eight-fold range of postdischarge mortality during the 30 or 90 days following an index hospitalization, and up to a four-fold range of risk for rehospitalization for heart failure during the ensuing 30 or 90 days. More on this study is available at Cardiology News: http://www.ecardiologynews.com/specialty-focus/heart-failure/single-article-page/aha-three-measures-risk-stratify-acute-heart-failure/db179da4df9d20baa44be88152c1598f.html.